Deploying Cost-Effective & Scalable Complex in vitro Models to De-Risk Your Translational Development
The FDA Modernization Act 2.0 has triggered a new mindset for pharma, with Roche launching the Institute of Human Biology to create better models, and MSD collaborating with Inventia to bioprint 3D in vitro models to screen for neurodegenerative therapeutic candidates.
It has never been a more exciting time to bet on 3D tissue models as the future of drug development, as more and more complex in vitro models undergo validation. However, the big question of “ Are they going to be economically viable as a drug development tool, what is the return on investment for us, and how to do it at scale?” persists at the forefront of biopharma leaders’ thoughts.
Making its timely return to Boston this May, the 9th 3D Tissue Models Summit will enable you and your team to uncover best practices of complex in vitro model use across drug discovery and development through 23+ practical case studies. Join us to learn from and meet the ‘front-line’ experts optimizing and leveraging advanced 3D tissue models to confidently empower your own drug development workflows in a time-efficient and cost-effective way.
A Snapshot of What to Expect in 2024:
Uncover best practice to interrogate renal pathophysiology using 3D ex vivo cell culture with Pfizer to supercharge the target validation process
Discover methodologies to validate the pathobiology of lung organoid and organ-on-a-chip models with Boehringer Ingelheim to better support candidate efficacy studies
Interrogate the big question of model complexity with Merck to uncover how the study question can affect model design and use
Explore optimized strategies to maintain model replicability within intestinal organoids with Regeneron to ensure efficient scaling up in drug discovery endeavours
Understand techniques to employ microfluidic devices across early drug discovery with Alchemab Therapeutics to probe the blood-brain barrier for drug development
Expert Speakers Include:
Current Companies in the Room:
Expert Partners in 2024:
